Stocks · News reference

OKYO Pharma Says Gary Jacob, Chief Development Officer And Director, Increases His Holdings With Purchase Of 3,500 Ordinary Shares On NASDAQ At $1.40 Per Share

Jul 22, 2026, 2:02 PMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaJul 28, 2026, 11:08 AMBenzinga Newsdesk
OKYO Pharma Says Chief Scientific Officer Raj Patil Purchases Of 3,363 Of Ordinary Shares On NASDAQ At $1.49 Per Share
OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced
OKYO
BenzingaJul 23, 2026, 4:03 PMBenzinga Newsdesk
OKYO Pharma Announces Non-Executive Director John Brancaccio Buys 5,000 Shares At $1.48/Share, Bringing Total Holdings To 35,201 Shares
OKYO
BenzingaJul 23, 2026, 11:01 AMBenzinga Newsdesk
OKYO Pharma Says CEO Robert Dempsey Purchases 15,000 Of Its Ordinary Shares On NASDAQ At $1.54 Per Share
OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced
OKYO